Pharmaceuticals
A Commitment to India for Over 125 Years
Bayer has been present in India for over 125 years, introducing its pharmaceutical products to the country in the early 1900s. Since then, the company has remained committed to its purpose of helping meet the evolving healthcare needs of the population.
With a population of 1.46 billion, India today represents about one-fifth of the world’s people and bears one of the highest burdens of certain diseases globally.
Driving Innovation and Access
Today, Bayer’s presence in the Indian pharmaceutical market is driven by a strategic commitment to introducing first-in-class, innovative therapies across key areas such as Cardiovascular Health, Diabetes, Kidney Health, Women’s Healthcare, Oncology, and Ophthalmology. In all these areas, our global innovative brands hold leadership positions.
Innovation alone isn’t enough, and thus, Bayer is equally focused on improving access to these advancements for patients across the region. By making innovative treatments more accessible, Bayer aims to significantly improve health outcomes and enhance the quality of life for patients across India.
Pharmacovigilance – Unwavering Focus on Patient Safety
Patient safety is at the heart of everything we do. Our comprehensive pharmacovigilance framework continuously monitors our medicines and medical devices throughout their entire lifecycle, ensuring that every product upholds the highest standards of safety and efficacy.
With a team of over 1,000 global pharmacovigilance experts, Bayer remains at the forefront of side-effect analysis, risk mitigation, and prevention strategies, reinforcing our promise to safeguard patients at every step of their treatment journey.